AJR InPractice
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vogl, T. J.
Right arrow Articles by Western, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vogl, T. J.
Right arrow Articles by Western, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?

American Journal of Roentgenology, Vol 163, 425-432, Copyright © 1994 by American Roentgen Ray Society

ARTICLES

MR diagnosis of head and neck tumors: comparison of contrast enhancement with triple-dose gadodiamide and standard-dose gadopentetate dimeglumine in the same patients

TJ Vogl, MG Mack, M Juergens, M Stark, W Pegios, C Bergman, G Grevers and A Western
Department of Radiology, University of Berlin, Rudolf Virchow Hospital, Germany.

OBJECTIVE. The purpose of this study was to compare the relative values of MR images obtained with a triple dose of gadodiamide and MR images obtained with the standard dose of gadopentetate dimeglumine for the detection and determination of the extent of tumors of the head and neck. MATERIALS AND METHODS. Forty-two patients with benign and malignant tumors of the head and neck were examined with contrast- enhanced MR imaging in a comparison of a triple dose of gadodiamide (0.3 mmol per kilogram body weight) and a standard dose (0.1 mmol per kilogram body weight) of gadopentetate dimeglumine. All patients underwent MR imaging with both doses of contrast material. Contrast-to- noise ratios and the percentage enhancement of normal and abnormal structures were calculated, and delineation of the lesion and the contrast between tumor and surrounding tissue were evaluated visually. RESULTS. Statistical analysis (Friedman test and Wilcoxon test) of the contrast-to-noise ratios between tumor and white matter, the percentage enhancement, and the visual assessment rating revealed a statistically significant superiority of the triple dose of gadodiamide over the standard dose of gadopentetate dimeglumine. Tumor/muscle contrast-to- noise ratios were not significantly different with the two doses. The detection rate for tumors was no better with the triple dose of gadodiamide than with the standard dose of gadopentetate dimeglumine. CONCLUSION. Use of the triple dose of gadodiamide results in a statistically significant improvement in the visual assessment rating, but it does not increase the number of tumors detected on MR images over the number detected with the standard dose of gadopentetate dimeglumine and does not appear to alter the differential diagnosis.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Neuroradiol.Home page
R. Kuo, J.K. Huang, K.S. Lee, B.F. Chen, and F.S. Yang
Leiomyosarcoma in the Nasopharynx: MR Imaging Findings
AJNR Am. J. Neuroradiol., August 1, 2007; 28(7): 1373 - 1374.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Roentgen Ray Society.